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Abstract: The therapeutic agents currently used to treat schizophrenia effectively improve psychotic symptoms; however, 
they are limited by adverse effects and poor efficacy when negative symptoms of the illness and cognitive dysfunction are 
considered. While optimal pharmacotherapy would directly target the neuropathology of schizophrenia neither the under-
lying neurobiological substrates of the behavioral symptoms nor the cognitive deficits have been clearly established. Ab-
normalities in the neurotransmitters dopamine, serotonin, glutamate, and GABA are commonly implicated in schizophre-
nia; however, it is not uncommon for alterations in the brain cholinergic system (e.g., choline acetyltransferase, nicotinic 
and muscarinic acetylcholine receptors) to also be reported. Further, there is now considerable evidence in the animal lit-
erature to suggest that both first and second generation antipsychotics (when administered chronically) can alter the levels 
of several cholinergic markers in the brain as well as impair memory-related task performance. Given the well-established 
importance of central cholinergic neurons to information processing and cognition, it is important that cholinergic func-
tion in schizophrenia be further elucidated and that the mechanisms of the chronic effects of antipsychotic drugs on this 
important neurotransmitter system be identified. A better understanding of these mechanisms would be expected to facili-
tate optimal treatment strategies for schizophrenia as well as the identification of novel therapeutic targets. In this review,
the following topics are discussed: 1) the central cholinergic system in schizophrenia 2) effects of antipsychotic drugs on 
central cholinergic neurons 3) important neurotrophins in schizophrenia, especially those that support central cholinergic 
neurons; 4) novel strategies to optimize the therapeutics of schizophrenia via the use of cholinergic compounds as primary 
(i.e., antipsychotic) treatments as well as adjunctive, pro-cognitive agents. 
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INTRODUCTION 
  Schizophrenia is a chronic neuropsychiatric illness that 
affects approximately 1% of the world’s population. Core 
features of the disease [reviewed, 3] include positive symp-
toms (e.g., hallucinations, delusions), negative symptoms 
(e.g., anhedonia, alogia, depression) and cognitive dysfunc-
tion (e.g., impaired working memory, attention, cognitive 
flexibility). This debilitating array of clinical symptoms 
commonly requires life-long therapeutic intervention. The 
primary therapeutic agents used for schizophrenia (i.e., the 
antipsychotic drugs) have been shown in multiple clinical 
trials to improve the behavioral (i.e., primarily positive) 
symptoms in most schizophrenic patients. However, the 
older, conventional agents (also referred to as typical or first 
generation antipsychotics) are limited by a number of ad-
verse reactions including motor effects (e.g., Parkinsonian 
symptoms and tardive dyskinesia). Likewise, the newer 
agents (referred to as atypical or second generation antipsy-
chotics) are now associated with several long term side ef-
fects including abnormal weight gain, development of diabe-
tes mellitus, and hyperlipidemias [reviewed, 35]. 
  An important limitation to strategies for novel drug de-
velopment is the relatively poor understanding of the neuro-
pathology of schizophrenia. In postmortem brains of schizo-
phrenic patients, evidence of reduced neuronal size, neuropil 
loss (particularly synaptic elements), decreased cortical   
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volume, and abnormal synaptic organization is substantial 
[39]. In addition, abnormalities in the neurotransmitters do-
pamine, serotonin, glutamate, and GABA (and their recep-
tors) are also commonly implicated the neuropathology of 
schizophrenia. While the abnormalities described above are 
widely postulated to be neurodevelopmental in origin, the 
brains of antipsychotic-naïve schizophrenic patients have 
only rarely been analyzed. Thus, the possible contribution of 
chronic drug exposure to such neuropathological findings 
and neurotransmitter alterations is largely unexplored. In 
addition to the neurotransmitter receptor abnormalities de-
scribed above, both the therapeutic actions and adverse ef-
fects of antipsychotic drugs have for decades been attributed 
to their relative affinities for specific neurotransmitter recep-
tors [98]. The mechanism of action of conventional antipsy-
chotics is most often attributed to their high affinity as an-
tagonists at the dopamine (D2) receptor subtype in the CNS, 
whereas the mechanism of newer, second generation com-
pounds is commonly attributed to a weaker affinity at D2
receptors combined with antagonist activity at other sites, 
such as the 5HT2A serotonin receptor [reviewed, 66]. It 
should be noted, however, that such receptor interactions 
occur almost instantaneously whereas many of the therapeu-
tic effects and adverse reactions of antipsychotics can be 
observed only after chronic treatment periods. Thus, collec-
tively, the information described above indicates that neither 
the neuropathology of schizophrenia nor the mechanism of 
action of effective therapeutic modalities is well understood. 
There is, therefore, a critical need for additional (i.e., more 
extensive) research to improve our understanding of both of 
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tion limits decisions concerning optimal therapeutic strate-
gies as well as the development of new treatments for 
schizophrenia.  
THE CHOLINERGIC SYSTEM IN SCHIZOPHRENIA 
  Notwithstanding the neurotransmitter anomalies de-
scribed above, it is also not widely appreciated that altera-
tions in markers for the neurotransmitter, acetylcholine have 
been commonly reported in schizophrenia [80, 91]. Such 
data may be significant to both the psychotic symptoms and 
the cognitive deficits of the illness. Cholinergic deficits in 
basal forebrain structures and their projections in schizo-
phrenia (see below) may be of particular importance to the 
cognitive dysfunction given their known functional roles in 
conscious awareness, and components of information proc-
essing, including attention, working memory, encoding, 
memory consolidation, and retrieval [36, 74].  
  It has been known for many years that anticholinergic 
compounds when administered in high doses can induce 
psychosis. For example, muscarinic antagonists such as sco-
polamine or atropine can evoke a psychotic state termed “an-
ticholinergicsyndrome” or “antimuscarinic psychosis” which 
shares many features with endogenous schizophrenia [18, 42, 
56, 61, 64, 72, 73, 102, 105]. Other non-selective mAChR 
antagonists (e.g., Ditran) were also found to induce psycho-
sis in normal humans and to exacerbate the symptoms of 
schizophrenia [68]. Further, the antimuscarinic agent, pro-
cyclidine, was reported to block the effects of the conven-
tional antipsychotic flupenthixol on positive symptoms in 
schizophrenia patients [45].  
  For more than 30 years alterations in the acetylcholine 
synthesizing enzyme, choline acetyltransferase (ChAT), in 
schizophrenia have been reported [see ref 55]. Examples 
include ChAT alterations in the septum [60], nucleus accum-
bens, and pontine tegmentum [8, 46]. Elevated levels of cho-
line, the precursor to acetylcholine, have also been detected 
via magnetic resonance spectroscopy in thalamic, anterior 
cingulate, and caudate nucleus regions of antipsychotic-naïve 
patients [15, 95], possibly indicative of impaired ChAT ac-
tivity.  
  There is also considerable evidence of muscarinic acetyl-
choline receptor (mAChR) alterations (particularly M1 and 
M2) in schizophrenia. These mAChR subtypes are known to 
play important roles in several signaling pathways that 
modulate neuronal excitability, synaptic plasticity, and learn-
ing and memory [97, 99]. Further, these mAChR subtypes 
are the ones expressed in highest quantities in the mammal-
ian brain. Older studies reported increased M2/M4 receptor 
binding in the orbital frontal cortex and putamen [70, 100] 
and decreased binding in frontal, parietal, and temporal cor-
tices [6] in schizophrenic brains, while more recent studies 
indicate decreases in M1/M4 receptor binding in the striatum, 
hippocampal formation, prefrontal cortex, and anterior cin-
gulate cortex [25, 22, 47]. Deficits in M2/M4 receptors as 
well as cholinergic interneurons in the striatum of schizo-
phrenic brains have also been reported [21].  
  There is also credible evidence to support the argument 
that both high and low affinity nicotinic acetylcholine recep-
tors(nAChRs) are diminished in schizophrenia. High-affinity 
(heteromeric 42 subunit complexes) and low-affinity (ho-
momeric7) nAChRs are ligand (i.e., neurotransmitter) gated 
ion channels that have been implicated in a variety of learn-
ing and memory processes [52]. In mammalian brain, the 
42 nAChR subtype of high-affinity nAChR predominates 
in density and distribution compared with other subtypes 
[75]. Several comparative autoradiographic studies of post-
mortem tissues from schizophrenic patients indicate de-
creased 42 nAChR binding in several brain regions includ-
ing the striatum, hippocampus, and cortex compared with 
controls [11, 27, and review, 33]. There is also significant 
evidence of alterations in low affinity 7 nAChR deficits in 
schizophrenia. 7 nAChRs comprise approximately 10% of 
the total number of nAChRs in mammalian brain, but modu-
late a variety of calcium-dependent events in neurons includ-
ing neurotransmitter release [37, 59], postsynaptic signaling 
[17, 41] and neuronal survival [7, 62]. Evidence of 7
nAChR alterations in schizophrenia includes postmortem 
deficits in the hippocampus and frontal cortex [38] and link-
age analyses implicating chromosome 15q14 (the region that 
includes the 7 neuronal nAChR gene). Polymorphisms in 
thecorepromoterofthe 7 neuronal nAChR gene (CHRNA7; 
GeneBank accession no. Z23141) are associated altered P50 
evoked responses to repeated auditory stimuli (i.e., indicative 
of sensory gating abnormalities) in schizophrenia [reviewed, 
32]. 7 nAChR deficits may also contribute to other abnor-
malities in schizophrenia including deficits in smooth pursuit 
eyemovements,sustained attention, and cognition [reviewed, 
57]. Collectively, these findings have lead to the suggestion 
that a reduction in 7 nAChR expression could potentially 
serve as a biomarker for schizophrenia [34, 76]. 
RELEVANT NEUROTROPHINS 
  The important role of neurotrophins in the pathophysiol-
ogy and pharmacotherapy of schizophrenia is gaining inter-
est [14, 85]. Neurotrophins, including nerve growth factor 
(NGF) and brain-derived neurotrophic factor (BDNF), and 
their respective receptors serve important roles in neurode-
velopment [58], while, in the mature nervous system, they 
promote neuronal survival and modulate synaptic plasticity 
of dopaminergic, serotonergic, and interestingly, cholinergic 
neurons [30, 23, 50]. Like NGF [20, 51], BDNF promotes 
survival and differentiation of basal forebrain cholinergic 
neurons [29], stimulates the release of acetylcholine [49] and 
supports the maintenance of synaptic plasticity and cognitive 
processes [67]. To date, however, only a relatively few stud-
ies have been designed to investigate the potential role of 
neurotrophin alterations in schizophrenia. Bersani and col-
laborators [9] reported diurnal plasma fluctuations in NGF 
(i.e., higher levels in the morning and lower levels in the 
evening in schizophrenics, compared to controls), while 
Parikh et al., 2003 [71] detected lower plasma NGF levels 
(compared to controls) in first episode, never medicated 
schizophrenic patients, as well as chronically-treated pa-
tients. Regarding BDNF, in one postmortem study, signifi-
cant increases in cortical areas and significant decreases in 
the hippocampus were detected in schizophrenic patients 
compared with controls. [28]. Takahashi et al., 2000 [87], 
detected elevated levels of BDNF specifically in the anterior 
cingulate cortex and hippocampus of schizophrenic patients, 
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campus and prefrontal cortex. In another study, both BDNF 
and TrkB mRNA levels were significantly decreased in the 
prefrontal cortex of subjects with schizophrenia [40].  
  The effects of antipsychotics on neurotrophins are even 
less well-understood and, to date, most conclusions rely on 
animal studies. In rodents, both acute (3 days) and sub-
chronic (21 days) exposure to haloperidol decreased the lev-
els of BDNF in the prefrontal cortex, hippocampus, and 
amygdala. Decreased BDNF concentrations [4] and de-
creased expression of BDNF mRNA [54] were also observed 
after risperidone and clozapine administration. Angelucci 
and collaborators [4] reported that subchronic (29 day) 
treatment with haloperidol or risperidone in rats increased 
NGF immunoreactivity in the hypothalamus, but decreased 
levels in the striatum and hippocampus. These researchers 
more recently [5] found that 29 days of oral olanzapine 
treatment increased NGF in the hippocampus, occipital cor-
tex and hypothalamus, but decreased BDNF in the hippo-
campus and frontal cortex. The results of recent studies in 
our laboratory indicate that the effects of conventional and 
second generation antipsychotics on NGF are temporally 
dependent, specifically; they can be very different depending 
on the length of time of administration. Specifically, while 
NGF levels in the hippocampus were either unchanged or 
upregulated in rats in response to several antipsychotics dur-
ing short periods of treatment (7, 14, and 45 days) they were 
significantly decreased by haloperidol, chlorpromazine, 
olanzapine, and risperidone when continuously administered 
orally for 90 or 180 days [78, 90]. 
ANTIPSYCHOTICS AND CENTRAL CHOLINERGIC 
FUNCTION: DELETERIOUS EFFECTS 
  Taking into consideration the information provided 
above, an interesting question arises as to what extent antip-
sychotic drugs affect the central cholinergic system. The 
conventional antipsychotics, thioridazine and chlorpromaz-
ine, and the atypical agents, clozapine and olanzapine bind 
all of the known muscarinic acetylcholine receptor subtypes 
with relatively high affinity [reviewed, 16], although the 
significance of this binding to the therapeutics and adverse 
effects is unknown. Both conventional and atypical antipsy-
chotics have been observed to increase acetylcholine levels 
in the hippocampus of rats [84], although the effects of the 
atypical agents, clozapine and olanzapine, were more robust. 
Further, the atypical agents, clozapine, olanzapine, risperi-
done, and ziprasidone significantly increased acetylcholine 
release in rat medial prefrontal cortex, whereas the haloperi-
dol and thioridazine did not [44]. These differential effects 
on acetylcholine release were hypothesized (in the studies 
cited above) to underlie the reported superiority of atypical 
antipsychotics on cognitive function when compared to con-
ventional agents. However, it is unclear whether such effects 
would persist for extended periods of time (i.e., the more 
clinically relevant question regarding antipsychotics). It is 
also unclear whether such an acute effect would actually be 
beneficial to cognition; given the fact that muscarinic an-
tagonists such as atropine and scopolamine (i.e., drugs that 
impair cognition) are well-documented to acutely elevate 
acetylcholine levels in a number of regions of the brain in-
cluding the hippocampus and cortex [24, 65]. 
  There is significant evidence to indicate that chronic 
treatment with antipsychotic drugs alters cholinergic func-
tion. It has been known for many years that conventional 
antipsychotics can produce time-dependent (biphasic) cho-
linergic responses in the striatum of animals. This effect has 
been implicated as a potential mechanism of the adverse 
motor effects of conventional antipsychotic in humans. Spe-
cifically, an increase in the activity of cholinergic interneu-
rons in the striatum induced by conventional antipsychotics 
initially appears to correlate with the extrapyamidal side ef-
fects in humans, whereas more prolonged periods of expo-
sure correlate with decreases in cholinergic activity below 
baseline (i.e., effects that correspond with the emergence of 
tardive dyskinesia [63]. Such effects may also account for 
the ability of anticholinergic drugs such as benztropine and 
diphenhydramine to reduce extrapyamidal side effects of 
conventional agents during early use, and their lack of effi-
cacy (or tendency to exacerbate symptoms) in tardive dyski-
nesia. In light of a possible cholinergic basis for antipsy-
chotic-related extrapyramidal effects and TD, another logical 
question arises as to whether such cholinergic effects might 
influence information processing and cognition, since cho-
linergic interneurons in the striatum are now known to ex-
hibit long term potentiation (LTP) and to play an important 
role procedural learning [48]. We recently detected biphasic; 
time-dependent effects of both first and second generation 
antipsychotics in memory-related brain areas such as the 
hippocampus in rats [90, 91, 94]. In fact, we now have con-
vincing evidence of time-dependent changes resulting from 
antipsychotics in the vesicular acetylcholine transporter, the 
cholinergic enzyme, choline acetyltransferase, as well as 
nicotinic (7) and muscarininc (M2) acetylcholine receptors 
[88, 89, 90, 93]. As in the case of the unexplained mecha-
nisms that underlie the time dependence of the therapeutic 
effects of antipsychotic drugs (discussed in the Introduction), 
the mechanisms for the long term antipsychotic-related cho-
linergic alterations are unknown. We have proposed two 
potential mechanisms: antipsychotic antagonist activity at 
dopaminergic-D2 receptors on cholinergic neurons (leading 
to cholinergic dysregulation) and, adverse antipsychotic ef-
fects on neurotrophins that support cholinergic neurons such 
as nerve growth factor and brain derived growth factor (see 
review [91]).  
ANTIPSYCHOTICS AND CENTRAL CHOLINERGIC 
FUNCTION: THERAPEUTIC IMPLICATIONS 
  Reports of cholinergic deficits in schizophrenia (de-
scribed above), have given rise to cholinergic strategies for 
improving both the psychotic symptoms and cognitive defi-
cits in schizophrenia. More than 50 years ago Pfeiffer and 
Jenney [77] reported antipsychotic effects of the choli-
nomimetic compound arecoline in schizophrenic patients. 
Further, acetylcholinesterase inhibitors (e.g., donepezil, gal-
antamine) [reviewed, 103] and the muscarinic M1/M4 prefer-
ring receptor agonist, xanomeline have been reported to im-
prove behavioral symptoms in Alzheimer's disease patients 
[10]. This information combined with the aforementioned 
cholinergic deficits observed in schizophrenia has provided 
the basis for the idea of evaluating compounds such as ace-
tylcholinesterase inhibitors (AChEIs), mAChR agonists, 
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nAChRs as therapeutic agents in schizophrenia [reviewed, 
33, 19]. Among these approaches, one that appears to be 
gaining momentum is the evaluation of mAChR agonists and 
allosteric activators of mAChRs. Neurochemical and behav-
ioral studies in mAChR-mutant mice indicate that M1 and/or 
M4 receptors (in particular) might serve as important thera-
peutic targets for schizophrenia [reviewed, 101]. Accord-
ingly, the M1/M4 preferring muscarinic agonist, xanomeline 
(in addition to its positive effects on the behavioral symp-
toms of AD noted above) demonstrates an antipsychotic-like 
profile in the rat [86] and it has been shown to improve both 
positive and negative symptoms in schizophrenic patients 
(study published in abstract form, [83]). Most recently, 
highly selective allosteric potentiators of the M4 mAChR 
(e.g., VU10010) and the M1 mAChR (TBPB) have been de-
veloped and shown to have robust effects in several animal 
models commonly used to predict antipsychotic activity [re-
viewed, 19]. Clinically, the approach that has been evaluated 
most extensively to date (i.e., and published) has been the 
adjunctive administration of AChEIs (i.e., with antipsychot-
ics) to improve cognitive function. The data from some of 
the studies have been equivocal; the beneficial cognitive 
effects of donepezil or rivastigmine as add-on treatments 
observed in preliminary open-label studies and case reports, 
were not confirmed in randomized, double-blind, and pla-
cebo controlled studies [31, 82]. More recently, a small, ran-
domized, double-blind clinical trial (N=8) indicated that ad-
junctive treatment with the AChEI, galantamine, improved 
short-term memory and attention in schizophrenic or 
schizoaffective patients who were stabilized on risperidone 
[81]. Most recently, 86 schizophrenia patients were evalu-
ated in a 12-week double-blind, placebo-controlled, random-
ized clinical trial with 42 subjects assigned to galantamine 
and 44 patients assigned to placebo [13]. The treatment ef-
fect for the overall composite score was not significant; 
however, follow-up analyses indicated improvements in 
processing speed and verbal memory. While such data are 
encouraging, additional studies will be required to verify the 
validly of adjunctive cholinesterase inhibitors as a reliable 
therapeutic approach to cognition enhancement. 
  As we have reviewed previously [91] there may be sev-
eral factors that underlie the equivocal nature of the studies 
cited above, such as cigarette smoking (and thus the con-
founding cholinergic receptor effects of nicotine) by the re-
search subjects, exposure to other drugs of abuse, differences 
in the neuropsychological measures employed, etc. Interest-
ingly, smoking rates in the schizophrenic population in North 
America have been reported to approach 90 percent in some 
studies [43], i.e., more that three times the rate of the general 
population and considerably higher than for the rate ob-
served in other psychiatric conditions [26, 96]. A variety of 
hypotheses have been presented to explain this phenomenon 
including volitional (i.e., self-medication) attempts to over-
come certain schizophrenia symptoms such as depression, 
anxiety, and anhedonia (see [69] for review), nAChR deficit-
related impairments of information processing, psychomotor 
speed, and cognition [1, 53] as well as to reduce antipsy-
chotic-related side effects. There is evidence to support some 
of these hypotheses. Nicotine (for example) has been shown 
in a variety of animal and human studies to have anxiolytic 
effects  [79, 12], to improve information processing and cog-
nition [53] and to ameliorate some side-effects (e.g., 
akathisia, bradykinesia) associated with first generation an-
tipsychotics [2, 104]. 
  An important factor that could certainly influence re-
sponses to the adjunctive agent is the unique medication his-
tory of the study subject. Specifically, factors such as the 
history of antipsychotic drug exposure, the particular antip-
sychotic agent currently being administered, and how long 
the patient has been exposed to a particular antipsychotic, 
could be especially important to the adjunctive treatment 
response. In our chronic animal studies [88, 92], we have 
found that several antipsychotics can lead to decreases in 
specific cholinergic markers (e.g., 7 nAChRs in association 
with haloperidol and risperidone). Such findings may indi-
cate that a more patient specific (i.e., tailored) therapeutic 
approach (using specific types of cholinergic agents) that 
takes into account the unique medication history (and current 
antipsychotic therapy) of the patient may be necessary to 
improve the symptoms of schizophrenia  
CONCLUSIONS 
  The therapeutics of schizophrenia are particularly chal-
lenging given the heterogeneity of disease symptoms and our 
relatively poor understanding of the neuropathology. In order 
to effectively address the core features of the illness (i.e., 
positive, negative, and cognitive symptoms), novel strategies 
need to be designed that take in to account a number of im-
port patient-specific factors. These factors include the spe-
cific symptom profile, the unique medication history of the 
particular patient, and concurrent exposure to other drugs 
(e.g., nicotine). Reports of alterations in the brain cholinergic 
system in schizophrenic patients combined with animal data 
suggesting that chronic exposure to antipsychotics can lead 
to cholinergic alterations, provides the impetus for investi-
gating both primary and adjunctive cholinergic strategies to 
the pharmacotherapy of schizophrenia.  
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